Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-07-11 pm EDT			Pre-market 08:44:48 am
156.90 ^USD	-0.50%		156.36	-0.34%

Jul. 13	Earnings, inflation data confront resilient US stocks rally	RE
Jul. 11	S&P 500 ends down as tariffs sour sentiment	RE

Johnson & Johnson Says Phase 1b Trial Shows Promise for Bleximenib Combo in AML Treatment

Published on 06/12/2025 at 11:56

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Johnson & Johnson

Earnings, inflation data confront resilient US stocks rally	Jul. 13	RE
S&P 500 ends down as tariffs sour sentiment	Jul. 11	RE
FDA May Fast Track Drug Reviews for Lower US Prices	Jul. 11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	Jul. 11	MT
HSBC Adjusts Johnson & Johnson's Price Target to $180 From $184, Keeps Buy Rating	Jul. 11	MT
Wall St Week Ahead-Earnings, inflation data confront resilient US stocks rally	Jul. 11	RE
Morgan Stanley Adjusts PT on Johnson & Johnson to $171 From $169, Maintains Equalweight Rating	Jul. 10	MT
Jabil Inc. : Investing to stay ahead	Jul. 10
Major deals involving U.S. drugmakers and biotechs over the past decade	Jul. 09	RE
Transgene SA Announces Board Changes	Jul. 09	CI
Johnson & Johnson's Q2 Earnings Call Likely to Focus on Guidance, Tariff Impact, BofA Says	Jul. 09	MT
Company earnings: key dates for next week	Jul. 09
Trump says pharmaceutical tariffs could reach 200%	Jul. 08	RE
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	Jul. 08	MT
Volatility as a Strategy	Jul. 08
J&J: seeks FDA approval for Caplyta for schizophrenia	Jul. 08	CF
Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia	Jul. 08	CI
Johnson & Johnson Submits Supplemental NDA for Schizophrenia Treatment Caplyta	Jul. 08	MT
Nanobiotix: NBTXR3 device reclassified as a drug	Jul. 08	CF
Nanobiotix Reports Regulatory Harmonization, New Composition of Matter Patent Filed for JNJ-1900	Jul. 07	MT
Johnson & Johnson Unit Submits EMA Application to Extend Indication of Akeega for Prostate Cancer	Jul. 03	MT
J&J Unit Seeks Indication Extension for Cancer Drug Combo in EU	Jul. 03	MT
US FDA approves Regeneron's blood cancer therapy	Jul. 02	RE

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2024, Johnson & Johnson has 64 manufacturing facilities located in the United States (23), North America (7), Europe (21), Africa and Asia/Pacific (13). The United States accounts for 56.6% of net sales.

Employees

138,100

Sector

Pharmaceuticals

Calendar

Jul. 16 - Q2 2025 Earnings Release

More about the company